Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.43 USD
Change Today -0.63 / -6.26%
Volume 3.9M
ACHN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:32 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

achillion pharmaceuticals (ACHN) Snapshot

Open
$10.21
Previous Close
$10.06
Day High
$10.36
Day Low
$9.40
52 Week High
12/22/14 - $16.87
52 Week Low
05/7/14 - $2.45
Market Cap
1.1B
Average Volume 10 Days
2.1M
EPS TTM
$-0.70
Shares Outstanding
117.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACHILLION PHARMACEUTICALS (ACHN)

achillion pharmaceuticals (ACHN) Related Businessweek News

No Related Businessweek News Found

achillion pharmaceuticals (ACHN) Details

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections. The company’s drug candidates for treating chronic HCV infection comprise ACH-3102, a NS5A inhibitor, which completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor that is in Phase I clinical development; and Sovaprevir, a NS3 protease inhibitor, which completed Phase II clinical trial. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

67 Employees
Last Reported Date: 03/5/15
Founded in 1998

achillion pharmaceuticals (ACHN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $484.1K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $347.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $457.6K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $335.4K
Compensation as of Fiscal Year 2014.

achillion pharmaceuticals (ACHN) Key Developments

Achillion Pharmaceuticals, Inc.’s Executive Vice President and Chief Regulatory Officer Gautam Shah to Departure from the Company Effective March 31, 2015

On March 18, 2015, Dr. Gautam Shah, the Executive Vice President and Chief Regulatory Officer of Achillion Pharmaceuticals, Inc., provided notice of his departure from the Company effective March 31, 2015. Subject to Dr. Shah executing a release of all claims against the Company and its affiliates, Dr. Shah will be entitled to receive benefits pursuant to the terms of his employment agreement dated April 5, 2011. Dr. Shah will continue to be subject to the terms of a Non-Competition and Non-Solicitation Agreement and a Non-Disclosure and Assignment of Inventions Agreement previously entered into with the Company.

Achillion Pharmaceuticals, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015 10:45 AM

Achillion Pharmaceuticals, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015 10:45 AM. Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France. Speakers: Joseph Truitt, Chief Commercial Officer and Executive Vice President of Business Development.

Achillion Pharmaceuticals, Inc. Reports Unaudited Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Financial Guidance for 2015

Achillion Pharmaceuticals, Inc. reported unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2014. For the three months ended December 31, 2014, the company reported a net loss of $21.6 million, compared to a net loss of $13.4 million in the three months ended December 31, 2013. Loss from operations was $21,661,000 against $13,495,000 for the three months ended December 31, 2013. For the full year ended December 31, 2014, the company's net loss was $69.0 million, or $0.70 per share, compared to a net loss of $58.9 million for the year ended December 31, 2013, or $0.63 per share. Loss from operations was $69,426,000 against $59,477,000 for the year ended December 31, 2013 The company expects that research and development expenses during 2015 will be approximately $85 - $95 million and that net cash used in operating activities in 2015 will be approximately $100 - $110 million based on current operating plans, anticipated timelines and the estimated cost of clinical trials and product development programs. The net loss per share is anticipated to approximate $0.95 per share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACHN:US $9.43 USD -0.63

ACHN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,706 GBp -44.00
Bavarian Nordic A/S kr335.00 DKK -7.00
Bayer AG €137.89 EUR +2.70
Chimerix Inc $37.17 USD -2.31
Emergent Biosolutions Inc $30.13 USD -0.48
View Industry Companies
 

Industry Analysis

ACHN

Industry Average

Valuation ACHN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACHILLION PHARMACEUTICALS, please visit www.achillion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.